From: Management and outcome of patients supported with Impella 5.0 for refractory cardiogenic shock
Type of complication | Values |
---|---|
Major device malfunction, n (%) | 4 (10) |
Minor device malfunction, n (%) | 3 (8) |
Device displacement (intra-aortic or intraventricular moving), n (%) | 8 (20) |
 Including successful bedside repositioning, n | 6 |
Bleeding requiring transfusion during surgical implantation, n (%) | 7 (18) |
Bleeding requiring surgery after implantation, n (%) | 0 (0) |
RBC transfusion on MCS, units [IQR] | 4 [1.5–8] |
RBC transfusion by day on MCS, units [IQR] | 0.4 [0.1–1.2] |
Upper or lower limb ischemia on implantation site, n (%) | 1 (3) |
Thromboembolic events, n (%) | 1 (3) |
Major hemolysis, n (%) | 1 (3Â %) |
Suspected or minor hemolysis, n (%) | 3 (8Â %) |
Ventricular arrhythmia, n (%) | 3 (8) |
Device-related infection, n (%) | 7 (18) |
 Surgical site infection, n (%) | 4 (10) |
 Infected thrombus on the head of the pump, n (%) | 3 (8) |
 Bloodstream infection during MCS, n (%) | 5 (13) |